A phase 1/2 study of intermittent, high dose sunitinib in patients with advanced solid tumors.

Research output: Contribution to journalMeeting AbstractAcademic

Original languageEnglish
JournalJournal of Clinical Oncology
Volume35
DOIs
Publication statusPublished - 20 May 2017

Cite this